Table 1.
Baseline characteristics of participants, Alberta physical activity, and Breast Cancer Prevention Trial 2003–2006, n=320a
| Exercisers (n=160) | Controls (n=160) | |
|---|---|---|
| Baseline characteristic | Mean±s.d. | Mean±s.d. |
| Age (years) | 61.2±5.4 | 60.6±5.7 |
| Body composition measurements | ||
| Body mass index (kg/m2) | 29.1±4.5 | 29.2±4.3 |
| Intra-abdominal fat area (cm2) | 101.4±55.4 | 103.2±56.0 |
| Total body fat (kg) | 30.9±8.2 | 31.3±8.6 |
| Percent body fat | 42.2±4.9 | 42.4±5.7 |
| N (%) | N (%) | |
|---|---|---|
| Education (>high school) | 112 (70) | 102 (64) |
| White race/ethnicity | 144 (91) | 145 (91) |
| Median (IQR) | Median (IQR) | |
|---|---|---|
| Insulin (μIU/ml) | 6.2 (3.8–9.5) | 5.7 (3.4–8.9) |
| Glucose (mM) | 5.4 (4.9–6.1) | 5.3 (4.9–5.8) |
| HOMA-IR | 1.4 (0.9–2.4) | 1.4 (0.8–2.3) |
| IGF1 (ng/ml) | 117 (95–138) | 119 (100–141) |
| IGFBP3 (μg/ml) | 4.0 (3.5–4.5) | 3.9 (3.4–4.5) |
| Leptin (ng/ml) | 19.2 (13.5–25.6) | 20.9 (12.8–30.1) |
| Adiponectin (μg/ml) | 11.5 (9.1–17.2) | 12.5 (9.6–16.1) |
| Adiponectin/leptin | 0.63 (0.38–1.07) | 0.64 (0.37–1.09) |
| IGF1/IGFBP3 | 29.5 (25.9–33.6) | 30.5 (25.9–40.0) |
IQR, interquartile range; HOMA-IR, homeostasis model assessment of insulin resistance=fasting glucose (mM)×fasting insulin (μIU/ml)/22.5; IGF1, insulin-like growth factor 1; IGFBP3, insulin-like growth factor-binding protein 3.
a
There were no statistically significant differences at baseline between exercisers and controls for these variables.